Hallucinations, delusions, disorganized thinking, and an inability to feel emotion are only few of the hallmarks of schizophrenia, a severe psychopathology. Symptoms: Hallucinations (hearing or seeing things that aren't there), delusions (false beliefs), and disordered thinking (such as bouncing from subject to topic) are examples of what are known as "positive symptoms," or symptoms that exist in addition to normal experience. Negative symptoms are those that indicate a decline in normal functioning, such as an inability to feel emotion, a lack of drive, or an avoidance of social interaction. The most prevalent pharmacological therapy for schizophrenia is the use of antipsychotic drugs. These drugs are effective because they block brain receptors for dopamine, so lowering the dopamine activity that is considered to exacerbate positive symptoms in schizophrenia. Both conventional antipsychotics (including chlorpromazine and haloperidol) and atypical antipsychotics are widely used (such as clozapine, risperidone, and olanzapine) Targeted receptors and neurotransmitters/hormones: Dopamine is a neurotransmitter that may have a role in the development of positive symptoms of schizophrenia. By inhibiting dopamine receptors in the brain, antipsychotic drugs hope to alleviate the agitation, paranoia, and other negative effects associated with high dopamine levels. Glutamate is a neurotransmitter that may have a role in the depressive and apathetic traits characteristic of schizophrenia. Some atypical antipsychotics may act through affecting the brain's glutamate system, according to recent studies. Schizophrenia is considered to be impacted by both hereditary and environmental factors, making it a complicated condition with various causes. The heritability of schizophrenia has been estimated to be approximately 80% based on studies of twins. Recent studies have pinpointed a number of genes, including those involved in the dopamine and glutamate neurotransmitter systems, that may contribute to an individual's susceptibility to developing schizophrenia. Distinctions and processes in the brain as revealed by neuroimaging and other methods: Schizophrenia is characterized by structural abnormalities in the brain, as shown by MRIs. These include diminished gray matter in key brain areas such the prefrontal cortex, temporal lobes, and hippocampus. The prefrontal cortex, temporal lobes, and hippocampus are all important in cognitive functions including attention, memory, and emotion, and functional neuroimaging studies have indicated that people with schizophrenia exhibit aberrant activity in these areas. The aberrant connection between distinct brain areas in patients with schizophrenia has also been linked to the disorder's symptoms. Hallucinations, delusions, skewed thought patterns, and an inability to feel emotion are only some of the symptoms of schizophrenia, which is a severe mental illness. Multiple genes have been linked to an increased chance of acquiring the condition, suggesting a genetic and environmental interaction in its development. Antipsychotic medicine, which treats schizophrenia by inhibiting dopamine receptors, is widely used. Studies of the brains of people with schizophrenia have shown anomalies in brain structure and activity in certain areas, as well as improper connection between these regions, all of which may contribute to the signs and symptoms of the condition. 